FORMA AMORFA DE RITONAVIR

Ritonavir amorfo que no contiene más de un 10% de ninguna otra forma de ritonavir, caracterizado por el termograma DSC registrado a una velocidad de calentamiento de 5º/minuto y una temperatura de transición vítrea de aproximadamente 45ºC a aproximadamente 49ºC. This Application concerns the use of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SALEKI-GERHARDT, AZITA, BAUER, JOHN F, PATEL, KETAN, BURKAR, SANJAY R, SPIWEK, HARRY O
Format:	Patent
Sprache:	spa
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	SALEKI-GERHARDT, AZITA BAUER, JOHN F PATEL, KETAN BURKAR, SANJAY R SPIWEK, HARRY O
description	Ritonavir amorfo que no contiene más de un 10% de ninguna otra forma de ritonavir, caracterizado por el termograma DSC registrado a una velocidad de calentamiento de 5º/minuto y una temperatura de transición vítrea de aproximadamente 45ºC a aproximadamente 49ºC. This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ES2322759TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ES2322759TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ES2322759TT33</originalsourceid><addsrcrecordid>eNrjZJB08w_ydVRw9PUPcnNUcHFVCPIM8fdzDPMM4mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8a7BRsZGRuamliEhxsbEqAEADX8gUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMA AMORFA DE RITONAVIR</title><source>esp@cenet</source><creator>SALEKI-GERHARDT, AZITA ; BAUER, JOHN F ; PATEL, KETAN ; BURKAR, SANJAY R ; SPIWEK, HARRY O</creator><creatorcontrib>SALEKI-GERHARDT, AZITA ; BAUER, JOHN F ; PATEL, KETAN ; BURKAR, SANJAY R ; SPIWEK, HARRY O</creatorcontrib><description>Ritonavir amorfo que no contiene más de un 10% de ninguna otra forma de ritonavir, caracterizado por el termograma DSC registrado a una velocidad de calentamiento de 5º/minuto y una temperatura de transición vítrea de aproximadamente 45ºC a aproximadamente 49ºC. This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.</description><language>spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090626&DB=EPODOC&CC=ES&NR=2322759T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090626&DB=EPODOC&CC=ES&NR=2322759T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SALEKI-GERHARDT, AZITA</creatorcontrib><creatorcontrib>BAUER, JOHN F</creatorcontrib><creatorcontrib>PATEL, KETAN</creatorcontrib><creatorcontrib>BURKAR, SANJAY R</creatorcontrib><creatorcontrib>SPIWEK, HARRY O</creatorcontrib><title>FORMA AMORFA DE RITONAVIR</title><description>Ritonavir amorfo que no contiene más de un 10% de ninguna otra forma de ritonavir, caracterizado por el termograma DSC registrado a una velocidad de calentamiento de 5º/minuto y una temperatura de transición vítrea de aproximadamente 45ºC a aproximadamente 49ºC. This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB08w_ydVRw9PUPcnNUcHFVCPIM8fdzDPMM4mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8a7BRsZGRuamliEhxsbEqAEADX8gUA</recordid><startdate>20090626</startdate><enddate>20090626</enddate><creator>SALEKI-GERHARDT, AZITA</creator><creator>BAUER, JOHN F</creator><creator>PATEL, KETAN</creator><creator>BURKAR, SANJAY R</creator><creator>SPIWEK, HARRY O</creator><scope>EVB</scope></search><sort><creationdate>20090626</creationdate><title>FORMA AMORFA DE RITONAVIR</title><author>SALEKI-GERHARDT, AZITA ; BAUER, JOHN F ; PATEL, KETAN ; BURKAR, SANJAY R ; SPIWEK, HARRY O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ES2322759TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SALEKI-GERHARDT, AZITA</creatorcontrib><creatorcontrib>BAUER, JOHN F</creatorcontrib><creatorcontrib>PATEL, KETAN</creatorcontrib><creatorcontrib>BURKAR, SANJAY R</creatorcontrib><creatorcontrib>SPIWEK, HARRY O</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SALEKI-GERHARDT, AZITA</au><au>BAUER, JOHN F</au><au>PATEL, KETAN</au><au>BURKAR, SANJAY R</au><au>SPIWEK, HARRY O</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMA AMORFA DE RITONAVIR</title><date>2009-06-26</date><risdate>2009</risdate><abstract>Ritonavir amorfo que no contiene más de un 10% de ninguna otra forma de ritonavir, caracterizado por el termograma DSC registrado a una velocidad de calentamiento de 5º/minuto y una temperatura de transición vítrea de aproximadamente 45ºC a aproximadamente 49ºC. This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	spa
recordid	cdi_epo_espacenet_ES2322759TT3
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	FORMA AMORFA DE RITONAVIR
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SALEKI-GERHARDT,%20AZITA&rft.date=2009-06-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EES2322759TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true